TPG-owned clinical trials player raises new equity, debt
Novotech, an Asia-based clinical trials specialist controlled by TPG Capital, has secured USD 760m in new equity and debt financing at a post-deal valuation of approximately USD 3bn.
The company, which was said to be targeting a Hong Kong IPO, completed a USD 255m private placement with participation from global institutional investors, sovereign wealth funds, and specialist healthcare...
More on Australasia
Latest News
India's Innoven fractionalises venture debt fund
India’s Innoven Capital, a joint venture between UOB and Temasek Holdings-owned Seviora Holdings, has fractionalised a USD 50m venture debt fund using blockchain and smart contracts.
Australian needle-free vaccine start-up raises $23m
OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.
Temasek, A91, Kae back $135m round for India's HealthKart
Temasek Holdings, A91 Partners, and Kae Capital have invested USD 135m in Indian omnichannel wellness products retailer HealthKart.